Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.

Front Immunol · 2023 · PMC9936529 · PMID 36817448

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The tumour growth control benefit was significant when comparing the combination to TILT-123 monotherapy and non-significant albeit a clear trend when comparing to 11B12-1 monotherapy.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.